Atomoxetine is a CNS stimulant class medication that is used to treat attention deficit hyperactivity disorder, depression, fibromyalgia, and social anxiety. Suppliers of atomoxetine medications market it in the form of 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, and 100mg capsules. The main alternatives to atomoxetine are other CNS stimulants, such as methylphenidate, dextroamphetamine, and lisdexamfetamine. Atomoxetine differs in the mechanism of action compared to these medications, which are all associated with increased side-effects and risk of dependency. Consequently, atomoxetine can be said to have a superior safety profile to these substitute drugs. Following FDA approval for medical use in 2002, the earliest atomoxetine manufacturer and patent-filing company Eli Lilly began marketing the drug under the trade name Strattera. The producer’s patent, however, expired in 2010, paving the way for other manufacturers and atomoxetine suppliers. Companies Sandoz, Mylan, Teva, Greenstone, and Sun Pharma have since introduced their atomoxetine medications into the global pharmaceutical market. The drug has gained popularity throughout the years and has become widely prescribed, with over 2 million prescriptions registered yearly in the U.S. alone. Consequently, atomoxetine suppliers and distributors currently market both generic and trade name formulations of the drug. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified atomoxetine manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.